We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+58.72%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.79B
AUM Growth
+$202M
Cap. Flow
-$337M
Cap. Flow %
-18.85%
Top 10 Hldgs %
65.26%
Holding
83
New
17
Increased
15
Reduced
17
Closed
21

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$37.7M
2
CBAY
Cymabay Therapeutics
CBAY
+$25.1M
3
INCY icon
Incyte
INCY
+$16.8M
4
SYK icon
Stryker
SYK
+$16.7M
5
KURA icon
Kura Oncology
KURA
+$16.4M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$77.4M
2
DXCM icon
DexCom
DXCM
+$54.2M
3
IDXX icon
Idexx Laboratories
IDXX
+$34.1M
4
AZN icon
AstraZeneca
AZN
+$33.3M
5
ELAN icon
Elanco Animal Health
ELAN
+$27.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.24%
2 Consumer Staples 1.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INZY
26
DELISTED
Inozyme Pharma
INZY
$18.2M 1.02%
4,280,308
– –
ELAN icon
27
Elanco Animal Health
ELAN
$12.4B
$17.8M 1%
1,193,885
-2,416,139
-67% -$27.4M
ARGX icon
28
argenx
ARGX
$57.4B
$17M 0.95%
44,721
-33,465
-43% -$15.6M
YMAB
29
DELISTED
Y-mAbs Therapeutics
YMAB
$15M 0.84%
2,194,278
– –
PHVS icon
30
Pharvaris
PHVS
$2.39B
$14.3M 0.8%
+510,441
New +$10.3M
DYN icon
31
Dyne Therapeutics
DYN
$4.04B
$13.5M 0.75%
1,013,505
+328,372
+48% +$3.21M
AGEN
32
Agenus
AGEN
$249M
$13M 0.73%
782,812
+114,575
+17% +$1.9M
SVRA icon
33
Savara
SVRA
$1.13B
$11.2M 0.63%
2,382,835
+2,224,927
+1,409% +$8.53M
MIRM icon
34
Mirum Pharmaceuticals
MIRM
$6.89B
$10.4M 0.58%
352,397
+343,308
+3,777% +$10.4M
CABA icon
35
Cabaletta Bio
CABA
$439M
$9.75M 0.55%
+429,395
New +$7.22M
IMVT icon
36
Immunovant
IMVT
$8.09B
$9.38M 0.52%
222,553
+82,668
+59% +$3.04M
BSX icon
37
Boston Scientific
BSX
$65.8B
$7.57M 0.42%
+131,000
New +$6.99M
GPCR icon
38
Structure Therapeutics
GPCR
$3.49B
$7.13M 0.4%
174,838
-27,281
-13% -$1.56M
MLTX icon
39
MoonLake Immunotherapeutics
MLTX
$1.59B
$6.87M 0.38%
113,757
-179,048
-61% -$9.23M
PODD icon
40
Insulet
PODD
$11.3B
$4.12M 0.23%
+19,000
New +$3.26M
IRWD icon
41
Ironwood Pharmaceuticals
IRWD
$611M
$3.79M 0.21%
+331,099
New +$3.28M
BOLT icon
42
Bolt Biotherapeutics
BOLT
$7.36M
$3.08M 0.17%
137,722
– –
NXTC icon
43
NextCure
NXTC
$17.3M
$3.05M 0.17%
222,655
– –
DXCM icon
44
DexCom
DXCM
$27.6B
$2.48M 0.14%
20,000
-530,197
-96% -$54.2M
COO icon
45
Cooper Companies
COO
$13.7B
$1.51M 0.08%
+16,000
New +$1.34M
MASI
46
DELISTED
Masimo
MASI
$1.5M 0.08%
+12,800
New +$1.19M
NCNA
47
NuCana
NCNA
$5.37M
$1.39M 0.08%
937
-183
-16% -$419K
AGEN
48
CALL
Agenus
AGEN
$249M
$1.32M 0.07%
80,000
– –
FUSN
49
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$1.2M 0.07%
125,299
+8,200
+7% +$39.8K
MRNS
50
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.09M 0.06%
100,000
-220,600
-69% -$1.65M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2023 Portfolio in Review

As of Q4 2023, Sofinnova Investments held 83 positions worth $1.79B, up 13% from $1.59B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Sofinnova Investments withdrew a net $337M in Q4 2023, closing 21 positions and reducing 17 holdings. Its most notable exit was Idexx Laboratories, an estimated $34.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 86% a quarter earlier, followed by Consumer Staples.

Against the trend, Sofinnova Investments opened a new position in Eli Lilly worth $37.6M.

  • Sofinnova Investments's largest Q4 2023 buy was Eli Lilly: 64,525 shares worth $37.6M.
  • Sofinnova Investments added most to Stryker in Q4 2023, an estimated $16.7M increase.
  • Sofinnova Investments's biggest Q4 2023 reduction was Natera, cutting an estimated $77.4M.
  • Sofinnova Investments fully exited Idexx Laboratories in Q4 2023, selling an estimated $34.1M.
  • Sofinnova Investments's ten largest holdings make up 65% of its $1.79B portfolio in Q4 2023.
  • Sofinnova Investments opened 17 new positions and closed 21 in Q4 2023.
  • Sofinnova Investments's portfolio value rose 13% quarter-over-quarter to $1.79B.

Based on Sofinnova Investments's 13F filing for Q4 2023, filed 13 Feb 2024.